{
  "retracted": false,
  "timestamp": 1508716800000,
  "updates": [
    {
      "timestamp": 1550506110528,
      "identifier": {
        "doi": "10.1007/s00280-017-3433-3"
      },
      "type": "erratum"
    }
  ],
  "identifier": {
    "doi": "10.1007/s00280-017-3417-3"
  },
  "journal": "Cancer Chemotherapy and Pharmacology",
  "publisher": "Springer Nature",
  "title": "Erratum to: Phase 1 study of darolutamide (ODM-201), a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer"
}
